ABBV-722 not checked

AbbVie

FollowEvery change as it happens, and a Monday email
Stage
 
Next date
Phase 2 trial completes
Trials
2 active
8 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
Tested for
Systemic Sclerosis, Rheumatoid Arthritis
Main trialPhase 2/3
“Systemic sclerosis (SSc), also called scleroderma, is a rare long-term autoimmune disease that causes the body to make too much collagen (scar tissue), leading to hard, thick skin and sometimes damage to organs such as the lungs, heart, kidneys, or digestive system. An autoimmune disease is a condition where the body's immune system, which normally protects against germs, mistakenly attacks its own healthy tissues and organs. The study has 2 parts. The main goal of Part 1 is to evaluate the safety and efficacy (how well the study treatment works) of ABBV-2294 (combination of ABBV-722 and…”In the company’s words, NCT07933211 on ClinicalTrials.gov

Other drugs for Systemic Sclerosis

All 57 drugs for Systemic Sclerosis

Coming up2

Changes1

Last 90 days

Trials8

TrialPhaseCompletesWhat it tests
Phase 2/3Not yet recruiting Jun 2035 A Study to Evaluate the Safety and Efficacy (How Well the Study Treatment Works) of ABBV-2294 in Adult Participants With Systemic Sclerosis That Are Currently Receiving Local Standard of Care Treatment, and to Determine the Best Dose of ABBV-2294 to be Evaluated Further.
Phase 2Not yet recruiting Jul 2029 Platform Study of Targeted Therapies for Adults With Moderately to Severely Active Rheumatoid Arthritis
Phase 1Completed 23 Mar 2026 A Phase 1 Study of a Tablet Form of ABBV-722 Taken With and Without Food in Healthy Adult Participants
Phase 1Completed 5 Jun 2026 A Phase 1 Study of the Safety and How the Body Processes ABBV-722 and Upadacitinib After Multiple Oral Doses in Healthy Adult Participants
Phase 1Completed 25 Jun 2026 A Study to Assess How the Drug Moves Through the Body, Adverse Events, and Tolerability of Oral ABBV-722 Capsules of Single and Multiple Ascending Doses in Adult Participants and Single Doses in Adult Asian Participants
Phase 1Completed 2 Jul 2026 A Phase 1 Study to Assess the Effect of ABBV-722 on Ethinyl Estradiol and Levonorgestrel Drug Levels in Healthy Adult Female Participants
Phase 1Completed 21 Jul 2026 A Phase 1 Study to Assess the Effect of ABBV-722 on Midazolam, Digoxin, Pitavastatin, Metformin, and Sitagliptin Drug Levels in Healthy Adults.
Phase 1Completed 3 Sep 2026 A Phase 1 Study to Assess the Effect of Itraconazole on ABBV-722 in Healthy Adult Participants
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow ABBV-722

Following is part of Solo: you see every change to ABBV-722 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in